Jannah Thompson, MD
Urogynecology and Reconstructive Pelvic Surgery · Norton Shores, MINPI 1104089986
Payments from drug & device makers
Across 861 payments — averaging $550.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$377K
- Boston Scientific$52K
- Valencia Technologies Corporation$25K
- Astellas Pharma US Inc$16K
- Coloplast$1K
- AbbVie$732
- plus $2K from 26 others
Across 16 payments — averaging $1116.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$18K
What the payments were for
- Consulting fees$55,83312%
- Speaking & faculty fees$344,27073%
- Travel & lodging$56,61812%
- Food & beverage$17,0964%
- Education$3080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 615 | $377,265 |
| Boston Scientific | 74 | $52,210 |
| Valencia Technologies Corporation | 28 | $24,846 |
| Astellas Pharma US Inc | 42 | $16,070 |
| Coloplast | 14 | $1,101 |
| AbbVie(2 entities) | 24 | $732 |
| Axonics, Inc. | 7 | $259 |
| Femselect Inc. | 2 | $252 |
| Procept Biorobotics Corporation | 2 | $199 |
| Davol Inc. | 1 | $160 |
| Urogen Pharma, Inc. | 5 | $154 |
| Pfizer | 8 | $128 |
| Urovant Sciences Inc | 5 | $93 |
| Myovant Sciences Inc. | 1 | $91 |
| Inspire Medical Systems, Inc. | 1 | $87 |
| Ferring Pharmaceuticals Inc. | 5 | $69 |
| Sumitomo Pharma America, Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $51 |
| Amgen | 2 | $37 |
| Dendreon Pharmaceuticals LLC | 2 | $37 |
| Olympus America Inc. | 2 | $32 |
| Rochester Medical Corporation | 1 | $26 |
| Blue Earth Diagnostics | 1 | $23 |
| Johnson & Johnson | 2 | $22 |
| Merck | 1 | $21 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Cook Medical LLC | 1 | $17 |
| Palette Life Sciences, Inc. | 1 | $16 |
| Bayer | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 2 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$286,781
- ALTAVIVA$46,935
- eCoin Device Kit$24,545
- Solyx SIS System$17,813
- MYRBETRIQ$15,189
- UPSYLON$13,916
- Advantage System$10,450
- NURO$5,453
- GENERAL PELVIC ORGAN PROLAPSE$3,420
- GENERAL FEMALE SUI$1,650
- GENERAL - THERAPIES$1,525
- TITAN$744
- INTELLIS ADAPTIVESTIM$506
- BOTOX$436
- EnPlace$239
- ARISTA$160
- AquaBeam Robotic System$151
- Axonics r-SNM System$141
- SOLYX$114
- LithoVue$112
How this compares
$474,125 in reported general payments places this provider in the 95th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.
See all urogynecology and reconstructive pelvic surgery providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 167 | $105,976 |
| GemtesaVibegron | 133 | $72,243 |
| Estradiol | 272 | $20,032 |
| Mirabegron ErMirabegron | 19 | $6,991 |
| Solifenacin Succinate | 68 | $2,711 |
| Methenamine Hippurate | 12 | $1,092 |
| Cephalexin | 17 | $224 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $119 |
| Gabapentin | 12 | $94 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $46 |
| Ciprofloxacin Hcl | 11 | $27 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $23 |
| Diazepam | 15 | $22 |
| Tramadol Hcl | 23 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $16,070 | $105,976167 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $57 | $72,243133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.
Other urogynecology and reconstructive pelvic surgery in Norton Shores
- Jonathan ShawNorton Shores$2K
- Priyanka GuptaAnn Arbor$383K
- Salil KhandwalaDearborn$176K
- Melissa FischerRoyal Oak$144K
- Jason BennettGrand Rapids$102K
- Anne CameronBrighton$88K
- Roger BeyerKalamazoo$71K
- Jason CruffDearborn$23K
- John DelanceyAnn Arbor$11K
- Ali LuckWest Bloomfield$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.